

Biogel® PI Micro range

Chemotherapy agent permeation



Tested for use with chemotherapy agents

Permeability: ((Breakthrough time, BTT): is the time taken between the application of the test chemical into the test cell when the permeation rate reaches 0,01 µg/cm²/min detection (ASTM D6978-05)

Test temperature: For Cytotoxic agents 35°C ± 2°C

Agent tested	CAS no. (active ingredient)	Concentration	Biogel PI Micro REF 485	Biogel PI Micro Indicator System REF 483
			ASTM D6978-05	ASTM D6978-05
Bleomycin	9041-93-4	15 mg/ml	>240	>240
Busulfan	55-98-1	6 mg/ml	>240	>240
Carboplatin	41575-94-4	10 mg/ml	>240	>240
Carmustine*	154-93-8	3.3 mg/ml	10.0	>240
Cisplatin	15663-27-1	1 mg/ml	>240	>240
Cyclophosphamide	50-18-0	20 mg/ml	>240	>240
Cytarabine	147-94-4	100 mg/ml	>240	>240
Dacarbazine	4342-03-4	10 mg/ml	>240	>240
Doxorubicin Hydrochloride	23214-92-8	2 mg/ml	>240	>240
Ellence	56420-45-2	2 mg/ml	>240	>240
Etoposide	33419-42-0	20 mg/ml	>240	>240
Fludarabine	21679-14-1	25 mg/ml	>240	>240
Fluorouracil	51-21-8	50 mg/ml	>240	>240
Idarubicin	57852-57-0	1 mg/ml	>240	>240
Ifosfamide	3778-73-2	50 mg/ml	>240	>240
Irinotecan	100286-90-6	20 mg/ml	>240	>240
Mechlorethamine HCl	55-86-7	1 mg/ml	>240	>240
Melphalan	148-82-3	5 mg/ml	>240	>240
Methotrexate	59-05-2	25 mg/ml	>240	>240
Mitomycin C	50-07-7	0.5 mg/ml	>240	>240
Mitoxantrone	70476-82-3	2 mg/ml	>240	>240
Oxaliplatin	63121-00-6	2 mg/ml	>240	not tested
Paclitaxel	33069-62-4	6 mg/ml	>240	>240
Rituximab	174722-31-7	10 mg/ml	>240	>240
Thiotepa*	52-24-4	10 mg/ml	20.3	>240
Vincristine Sulfate	57-22-7	1 mg/ml	>240	>240

If the BTT for a single glove has been determined to be 240 min the assumption is that the BTT for Biogel indicator system, in the same range, will be equal or longer, and has therefore not been tested. In this case we simply indicate Not tested.

Find out more at www.molnlycke.com

Mölnlycke Health Care AB, P.O. Box 13080, Gamlestadsvägen 3 C, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00

The Mölnlycke, Biogel and Indicator trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care group of companies. ©2020 Mölnlycke Health Care AB. All rights reserved.

Note: The Biogel® PI Micro and Biogel® PI Micro Indicator® System surgical gloves are intended to be worn on the hands, usually in the surgical settings, to provide barrier against potentially infectious material and other contaminants.

In addition, these gloves were tested at an independent test facility for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs.

Breakthrough detection times may not reflect the actual duration of protection in the workplace due to other factors influencing the performance, such as temperature, abrasion, puncture, degradation etc.

Gloves used for protection against chemotherapy drug exposure should be selected specifically for the types of chemical used. Users should review this information with information provided with the drug e.g. drug labeling or material safety data sheets for the chemicals being used to determine an adequate level of protection for the intended use.

***Warning:** Do not use single gloves for protection against Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml). Consider to always double glove together with additional controls when handling chemotherapy drugs to avoid contact.

Performance level, breakthrough detection time



All times are in minutes



Biogel® PI Micro range

Chemical permeation

Permeability: (Breakthrough time, BTT): is the time taken between the application of the test chemical into the test cell to when permeation rate reaches 1 µg/cm²/min detection (EN 16523-1:2015 equivalent to EN 374-3)

Test temperature: For Chemicals 23°C ± 1°C

Chemical tested	CAS no. (active ingredient)	Concentration	Biogel PI Micro REF 485	Biogel PI Micro Indicator System REF 483
			EN 16523-1 1 µg/cm ² /min	EN 16523-1 1 µg/cm ² /min
Cidex OPA	643-79-8	100%	>480	>480
Ethyl alcohol (Ethanol)	64-17-5	100%	3	21
Formaldehyde	50-00-0	40%	210	>480
Glutaraldehyde	111-30-8	3%	>480	>480
Chorhexidine gluconate	18472-51-0	4%	>480	>480
Clorhexidine gluconate in 70% Isopropyl alcohol	18472-51-0	0.5%	>480	>480
Hydrogen peroxide	7722-84-1	30%	>480	>480
Isopropyl alcohol (Isopropanol)	67-63-0	100%	6.1	36
Methyl alcohol (Methanol)	67-56-1	100%	2.1	10
Methyl methacrylate in bone cement	80-62-6	100%	1.5	6.2
Mineral oil	8042-47-5	100%	81	>480
Peracetic acid	79-21-0	5%	<1	31
Phenol 7%	108-95-2	7%	10	69
Phenol 70%	108-95-2	70%	11	82
Sodium hypochlorite	7681-52-9	13%	>480	>480
Povidone iodine antiseptic	25655-41-8	30%	>480	>480
Povidone iodine scrub	25655-41-8	30%	>480	>480
Povidone iodine tincture	25655-41-8	10%	>480	>480
Povidone iodine antiseptic solution	25655-41-8	10%	>480	>480
Povidone iodine surgical scrub	25655-41-8	8%	>480	>480

If the BTT for a single glove has been determined to be 480 min the assumption is that the BTT for Biogel indicator system, in the same range, will be equal or longer, and has therefore not been tested. In this case we simply indicate Not tested.

The performance level for each glove is classified based on their breakthrough time (EN 16523-1) in accordance to EN 374-1.

Review Material Safety Datasheet for all chemicals to be used to determine the required protection level.

Recommendations should be made to users that adoption of a suitable gloving choice should be based on the type of exposure to the chemical that the glove will experience during wear.

Performance level, breakthrough detection time

not tested	Level 0 ≤10	Level 1 >10	Level 2 >30	Level 3 >60	Level 4 >120	Level 5 >240	Level 6 >480
------------	----------------	----------------	----------------	----------------	-----------------	-----------------	-----------------

All times are in minutes

Find out more at www.molnlycke.com

Mölnlycke Health Care AB, P.O. Box 13080, Gamlestadsvägen 3 C, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00
The Mölnlycke, Biogel, and Indicator trademarks, names and logos are registered globally to one or more of the
Mölnlycke Health Care group of companies. ©2020 Mölnlycke Health Care AB. All rights reserved. RNSU0882005 / ver 2022

